Claims for Patent: 6,858,576

Summary for Patent: 6,858,576

Title:	Methods for regulating gastrointestinal motility
Abstract:	Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Inventor(s):	Andrew A. Young, Bronislava Gedulin, Nigel Robert Arnold Beeley, Kathryn S. Prickett
Assignee:	Amylin Pharmaceuticals LLC
Application Number:	US08/908,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,858,576
Patent Claims:	1. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin effective for reducing gastric motility. 2. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin effective for delaying gastric emptying. 3. The method according to claim 1 or 2 wherein said exendin is exendin-3. 4. The method according to claim 1 or 2 wherein said exendin is exendin-4. 5. The method according to claim 1 or 2 wherein said subject is undergoing a gastrointestinal diagnostic procedure. 6. The method according to claim 5 wherein said gastrointestinal diagnostic procedure is a radiological examination. 7. The method according to claim 6 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging. 8. The method according to claim 1 or 2 wherein said subject is suffering from a gastrointestinal disorder. 9. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula: 1 5 10 Xaa1 Xaa2 Xaa3 Gly Thr Xaa4 Xaa5, Xaa6 Xaa7 Xaa8 15 20 Ser Lys Gln Xaa9 Glu Glu Glu Ala Val Arg Leu 25 30 Xaa10 Xaa11 Xaa12 Xaa13 Leu Lys Asn Gly Gly Xaa14 35 Ser Ser Gly Ala Xaa15 Xaa16 Xaa17 Xaa18-Z wherein: Xaa1 is His, Arg or Tyr; Xaa2 is Ser, Gly, Ala or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr or naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or Glu; Xaa8 is Leu, Ile, Val, pentylglycine or Met; Xaa9 is Leu, Ile, pentylglycine, Val or Met; Xaa10 is Phe, Tyr or naphthylalanine; Xaa11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa12 is Glu or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16 and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa18 is Ser, Thr or Tyr; and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof. 10. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula: 1 5 10 Xaa1 Xaa2 Xaa3 Gly Thr Xaa4 Xaa5, Xaa6 Xaa7 Xaa8 15 20 Ser Lys Gln Xaa9 Glu Glu Glu Ala Val Arg Leu 25 30 Xaa10 Xaa11 Xaa12 Xaa13 Leu Lys Asn Gly Gly Xaa14 35 Ser Ser Gly Ala Xaa15 Xaa16 Xaa17 Xaa18-Z wherein: Xaa1 is His or Arg; Xaa2 is Ser or Gly; Xaa3 is Asp or Glu; Xaa4 is Phe or naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or Glu; Xaa8 is Leu or pentylglycine Xaa9 is Leu or pentylglycine; Xaa10 is Phe or naphthylalanine; Xaa11 is Ile, Val or tert-butylglycine; Xaa12 is Glu or Asp; Xaa13 is Trp or Phe; Xaa14, Xaa15, Xaa16 and Xaa17 are independently selected from Pro, homoproline or N-methylalanine; Xaa18 is Ser or Tyr; and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof. 11. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula: 1 5 10 Xaa1 Xaa2 Xaa3 Gly Thr Xaa4 Xaa5, Xaa6 Xaa7 Xaa8 15 20 Ser Lys Gln Xaa9 Glu Glu Glu Ala Val Arg Leu 25 30 Xaa10 Xaa11 Xaa12 Xaa13 Leu Lys Asn Gly Gly Xaa14 35 Ser Ser Gly Ala Xaa15 Xaa16 Xaa17 Xaa18-Z wherein: Xaa1 is His, Arg or Tyr; Xaa2 is Ser, Gly, Ala or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr or naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or Glu; Xaa8 is Leu, Ile, Val, pentylglycine or Met; Xaa9 is Leu, Ile, pentylglycine, Val or Met; Xaa10 is Phe, Tyr or naphthylalanine; Xaa11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa12 is Glu or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16 and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa18 is Ser, Thr or Tyr; and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof. 12. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula: 1 5 10 Xaa1 Xaa2 Xaa3 Gly Thr Xaa4 Xaa5, Xaa6 Xaa7 Xaa8 15 20 Ser Lys Gln Xaa9 Glu Glu Glu Ala Val Arg Leu 25 30 Xaa10 Xaa11 Xaa12 Xaa13 Leu Lys Asn Gly Gly Xaa14 35 Ser Ser Gly Ala Xaa15 Xaa16 Xaa17 Xaa18-Z wherein: Xaa1 is His or Arg; Xaa2 is Ser or Gly; Xaa3 is Asp or Glu; Xaa4 is Phe or naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or Glu; Xaa8 is Leu or pentylglycine Xaa9 is Leu or pentylglycine; Xaa10 is Phe or naphthylalanine; Xaa11 is Ile, Val or tert-butylglycine; Xaa12 is Glu or Asp; Xaa13 is Trp or Phe; Xaa14, Xaa15, Xaa16 and Xaa17 are independently selected from Pro, homoproline or N-methylalanine; Xaa18 is Ser or Tyr; and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof. 13. The method according to claim 9, 10, 11, or 12 wherein said subject is undergoing a gastrointestinal diagnostic procedure. 14. The method according to claim 13 wherein said gastrointestinal diagnostic procedure is a radiological examination. 15. The method according to claim 14 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging. 16. The method according to claim 9, 10, 11, or 12 wherein said subject is suffering from a gastrointestinal disorder. 17. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for reducing gastric motility. 18. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for delaying gastric emptying. 19. The method according to claim 17 or 18 wherein said subject is undergoing a gastrointestinal diagnostic procedure. 20. The method according to claim 19 wherein said gastrointestinal diagnostic procedure is a radiological examination. 21. The method according to claim 20 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging. 22. The method according to claim 17 or 18 wherein said subject is suffering from a gastrointestinal disorder.